Results 31 to 40 of about 2,347,326 (232)

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

New England Journal of Medicine, 2002
BACKGROUND The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival.
A. Rosenwald, George W. Wright, W. Chan, J. Connors, E. Campo, R. Fisher, R. Gascoyne, H. Muller-Hermelink, E. Smeland, J. Giltnane, E. Hurt, Hong Zhao, Lauren Averett, Liming Yang, W. Wilson, E. Jaffe, R. Simon, R. Klausner, J. Powell, P. Duffey, D. Longo, T. Greiner, D. Weisenburger, W. Sanger, B. Dave, J. Lynch, J. Vose, J. Armitage, E. Montserrat, A. López-Guillermo, T. Grogan, T. Miller, M. LeBlanc, G. Ott, S. Kvaløy, J. Delabie, H. Holte, P. Krajči, T. Stokke, L. Staudt   +39 more
semanticscholar   +1 more source

Artesunate shows potent anti-tumor activity in B-cell lymphoma

Journal of Hematology & Oncology, 2018
Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some
Thea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, Sébastien Wälchli, Ole Christian Lingjærde, Baoyan Bai, Pierre Dillard, Theodossis A. Theodossiou, Toril Holien, Anders Sundan, Else Marit Inderberg, Erlend B. Smeland, June Helen Myklebust, Morten P. Oksvold   +13 more
doaj   +1 more source

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.

Cancer Cell, 2021
Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-origin subtypes and associated genomic lesions, but also by diverse cell types and cell states in the tumor microenvironment (TME).
C. Steen, Bogdan Luca, M. S. Esfahani, Armon Azizi, B. Sworder, B. Nabet, D. Kurtz, C. Liu, Farnaz Khameneh, R. Advani, Y. Natkunam, J. Myklebust, M. Diehn, A. Gentles, Aaron M. Newman, A. Alizadeh   +15 more
semanticscholar   +1 more source

Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile [PDF]

, 2009
The human REL proto-oncogene encodes a transcription factor in the nuclear factor (NF)-kappaB family. Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown to transform any mammalian lymphoid cell type.
Chin, M., Gilmore, T.D., Herscovitch, M., Waxman, D.J., Zhang, N.   +4 more
core   +2 more sources

B-cell multilobated lymphoma [PDF]

Cancer, 1983
A 59-year-old man was hospitalized for evaluation of cervical lymph node enlargement, and a diagnosis of a diffuse histiocytic lymphoma with B-cell markers was made. The unusual multilobated nature of the lymphoma cells is the subject of this study. The light and electron microscopic features are described and compared with those previously reported T ...
openaire   +2 more sources

Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.

Cancer Discovery, 2021
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogenous disease. Transcriptomic and genetic characterization of DLBCL have increased the understanding of its intrinsic pathogenesis and provided potential therapeutic targets ...
N. Kotlov, A. Bagaev, M. Revuelta, J. Phillip, M. Cacciapuoti, Zoya Antysheva, V. Svekolkin, E. Tikhonova, N. Miheecheva, N. Kuzkina, Grigorii Nos, F. Tabbò, F. Frenkel, Paola Ghione, M. Tsiper, N. Almog, N. Fowler, A. Melnick, J. Leonard, G. Inghirami, L. Cerchietti   +20 more
semanticscholar   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

An Unusual Presentation of B-Cell Lymphoma as a Large Isolated Epiglottic Mass: Case Report and Literature Review

Case Reports in Otolaryngology, 2016
Extranodal presentation of B-cell lymphoma is uncommon. Isolated primary epiglottic B-cell lymphoma is even rarer. To our knowledge, there has been only one description of isolated B-cell lymphoma presenting as a large epiglottic mass.
Changxing Liu, Sean Delaney, Tamara N. Brown   +2 more
doaj   +1 more source

Antibody therapy of pediatric B-cell lymphoma

Frontiers in Oncology, 2013
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease.
Friederike eMeyer-Wentrup, Verena ede Zwart, Marc eBierings   +2 more
doaj   +1 more source

Diffuse b-cell lymphoma

Journal of the Belgian Society of Radiology, 2011
Background: A 39-year-old patient took medical advice because of progressive fatigue, with nausea, fever, non specific abdominal pain, 3 weeks after coming back from Asia. He had been positive for HIV for 6 years. Blood tests show an increased CRP level (4 mg/dl, nl < 1 mg/dl).
Grosu, C, Danse, E, Dragean, A, Annet, L
openaire   +5 more sources